Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexmedetomidine + sufentanil is a drug combination used in various anesthetic and analgesic applications. This combination leverages the synergistic effects of both medications to provide enhanced pain relief while potentially reducing side effects associated with either drug alone[1][2]. Dexmedetetomidine is a highly selective α2-adrenergic receptor agonist with sedative, anxiolytic, and analgesic properties. Sufentanil is a potent opioid analgesic that acts primarily on μ-opioid receptors. When combined, these drugs demonstrate improved analgesic efficacy compared to either agent used individually[1][8]. The combination is commonly used in various clinical settings including: - Epidural labor analgesia[1] - Postoperative pain management via patient-controlled analgesia (PCA)[2][8] - Anesthesia for surgical procedures[5] - Awake fiberoptic intubation[4] Clinical studies have shown that this combination can reduce the required doses of each individual medication, potentially minimizing adverse effects while maintaining or improving analgesic efficacy[1][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dexmedetomidine + sufentanil.